Navigation Links
Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
Date:9/18/2008

TORONTO, Sept. 18 /PRNewswire/ - Trillium Therapeutics Inc., a privately-held biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders, announced today that it has secured $12 million in new financing from its existing investors, VenGrowth Private Equity Partners, BDC Capital and Canadian Medical Discoveries Fund (CMDF).

"We are fortunate to have the continued support of some of Canada's premier venture capital investors, especially under these trying market conditions," commented Trillium CEO Dr. Niclas Stiernholm. "These funds will allow us to advance several programs into clinical development, elevating the company to a new level and opening up new strategic possibilities in 2009."

Trillium will use the majority of the proceeds to fund clinical trials of its lead product candidate, TTI-1612, a recombinant growth factor under parallel development for the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. TTI-1612 is on track to begin clinical testing by the end of 2008, and two additional trials are projected to commence in 2009. The company's two preclinical programs, a CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases, continue to hold promise and to generate strong scientific and commercial interest.

"Our continued support for Trillium is driven by the quality of the lead program TTI-1612, the strong patent position around the exciting new immunoregulatory target CD200, and management's proven ability to execute partnerships," added Dr. Luc Marengere, of VenGrowth Private Equity Partners, Trillium's largest investor.

About Trillium: Trillium Therapeutics Inc. is a private biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as autoimmune and inflammatory disorders, as well as can
'/>"/>

SOURCE Trillium Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Althea Technologies Secures $12 M Credit Line to Continue Facility Growth and Expansion
2. Progenitor Cell Therapy Secures Industry Accreditation
3. BIOCOM Institute Secures Non-Profit Designation and Funding
4. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
5. OMTEC 2008 Boasts Record Attendance and Secures Premier Position as Must-attend for Orthopaedic Companies
6. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
7. Novasys Medical Secures $49.5 Million in Series D Financing to Expand Commercialization of Its Renessa(R) Treatment for Incontinence in Women
8. Veran Medical Technologies Secures $4.75M in First Institutional Funding
9. Northwest Secures US$4.0 Million in Debt Financing
10. D-Pharm Secures Funding From Israels Chief Scientists Office
11. Aerovance Secures $20 Million in Debt Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Tris Pharma, a specialty pharmaceutical company ... that it has been selected as an award winner ... 2014 Awards for Excellence competition in the Business ... of judges from SCORE (Counselors to America,s Small Business) ... honored at a gala event to be held on ...
(Date:8/27/2014)... City, OR (PRWEB) August 27, 2014 ... stands to reason that the next beverage craze is ... Technology announced today that formulators can use Stress Relief ... ingredient used in the making of a beverage, including ... release for stress-generated energy, channeling that power into rapid ...
(Date:8/27/2014)... Cranford, NJ (PRWEB) August 27, 2014 ... and services – has once again shown superiority when ... trial sponsor by completing the ePRO portion of their ... results. The Japan-based pharma chose WriteResult’s digital writing ... IBS trials – the first to complete drew data ...
(Date:8/26/2014)... LOS ANGELES , Aug. 26, 2014  NeuroSigma, ... sciences company established to develop bioelectronic technologies, today announced ... S-1 with the U.S. Securities and Exchange Commission relating ... stock. The number of shares to be offered and ... yet been determined. Jefferies LLC will act ...
Breaking Biology Technology:Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical ... therapeutics for,the treatment of solid and hematologic cancers, today ... upcoming conferences:, Rodman & Renshaw 10th Annual Healthcare ... Wednesday, November 12, 2008, 2:00 p.m. EST, ...
... MINNEAPOLIS, Nov. 3 ATS Medical, Inc.,(Nasdaq: ... state-of-the-art cardiac,surgery products and services, today announced ... development of the ATS Forcefield(TM),technology. The animal ... regarding the inhibition of platelet adhesion on ...
... Journal published,an article on October 29th describing the ... and featuring quotes from,President and founder Dr. Timothy ... Transfusions: New Efforts to Recycle Blood and Treat ... part of the "The Informed Patient",series written by ...
Cached Biology Technology:Sunesis to Present at Upcoming Conferences 2ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results 2ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results 3Wall Street Journal Highlights Blood Management, Strategic Healthcare Group LLC, and Dr. Timothy Hannon 2
(Date:8/28/2014)... most important crop-producing countries will be fully saturated with ... trends continue, according to a new study led by ... types can already be found in around half the ... advances at its current rate, scientists fear that a ... by pests within the next 30 years. , Crop ...
(Date:8/27/2014)... MADISON, Wis. The mechanical force that a single fungal ... seem vanishingly small, but it plays a heavy role in ... biology. In fact, it may not be too much of ... onto land without the ability to respond to the touch ... Jean-Michel An, a professor of agronomy at the University of ...
(Date:8/27/2014)... -- WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced that it ... units of common stock and warrants at a price ... million, prior to deducting underwriting discounts and commissions and ... warrants are immediately separable and will be issued separately.  ... consists of 2,000 shares of common stock and 2,000 ...
Breaking Biology News(10 mins):New study charts the global invasion of crop pests 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3
... major component in the spice turmeric, when combined with ... and neck cancer cell growth, researchers with UCLA,s Jonsson ... widely used in South Asian and Middle Eastern cooking, ... attributed to its anti-inflammatory effects. Previous studies have shown ...
... and tissues in our bodies grow, develop and interact ... microbial pathogens that invade our bodies and cause infectious ... the methods of culturing and studying human cells have ... impermeable surfaces. While such 2-D culturing and modeling efforts ...
... of Leeds plant scientists has uncovered a snapshot of evolution ... million years ago led flowers to make male and female ... week in the Proceedings of the National Academy of ... a perfect example of how diversity stems from such genetic ...
Cached Biology News:Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 2Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 3The world is not flat: Exploring cells and tissues in three dimensions 2The world is not flat: Exploring cells and tissues in three dimensions 3The world is not flat: Exploring cells and tissues in three dimensions 4100-million-year-old mistake provides snapshot of evolution 2
... Spring offers a large collection of ... fetal tissuea, cell lines, and mouse ... in pHD9 vector. The size of ... be from 200bp to 1000bp by ...
... The IDS Corticosterone kit is a competitive ... corticosterone in mouse or rat serum or ... sole, corticosteroid in rats and mice, and ... birds and reptiles. Most mammals produce both ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
Biology Products: